Autologous BCMA-targeting CAR T cells
S103-101
Phase 2 mab active
Quick answer
Autologous BCMA-targeting CAR T cells for Multiple Myeloma in Relapse is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Multiple Myeloma in Relapse
- Phase
- Phase 2
- Modality
- mab
- Status
- active